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Abstract: Mindfulness-based interventions have been increasingly evidenced to be effective 
in different mental illnesses but limited in schizophrenia. This single-blind, multisite random-
ized controlled trial tested the effects of a mindfulness-based psychoeducation group program 
(MPGP in addition to usual care) versus a conventional psychoeducation group program (CPGP) 
versus treatment-as-usual (TAU) alone, in schizophrenia spectrum disorders over a 6-month 
follow-up. In each of the two study sites (outpatient clinics), 69 outpatients with schizophrenia 
or its subtypes (N=138) were randomly allocated to one of the three study groups (n=46) after 
baseline measurements and underwent 6 months of intervention. Primary outcomes including 
patients’ mental state and rehospitalization rate and other secondary outcomes were assessed 
at entry and at 1 week and 6 months. One hundred and thirty-one (95%) participants completed 
the interventions assigned and one to two post-tests. Multivariate analyses of variance (followed 
by univariate contrast tests) indicated that the MPGP participants reported greater reductions 
in their psychotic symptoms (P=0.003) and length/duration of rehospitalizations (P=0.005) at 
6-month follow-up. Patients in the MPGP group also reported greater improvements in their 
insight into illness/treatment (P=0.0008) and level of functioning (P=0.002) than the CPGP 
and TAU alone at the 1-week and 6-month follow-up. Overall, the findings suggest that MPGP 
can be useful in improving the short- to medium-term clinical outcomes of outpatients with 
schizophrenia spectrum disorders, not only in terms of their mental state and risk of relapse but 
also their insight into illness/treatment and psychosocial functioning.
Keywords: mindfulness intervention, psychoeducation, functioning, insight into illness, psy-
chotic symptoms, rehospitalization, schizophrenia
Introduction
Schizophrenia patients, constituting more than half of those with severe mental illness 
in global communities,1 are characterized by profound disturbances and worsening in 
their cognition, emotion, and psychosocial functioning.2 These patients often experi-
ence high relapses and demands for mental health services. While there are increasing 
advanced antipsychotic medications to reduce the psychotic symptoms, many patients 
still experience disabling residual symptoms and impaired functioning. Different 
approaches to psychosocial interventions provide significant benefits in improving 
patients’ symptoms, drug compliance, and relapse, but inconsistent and inconclusive 
results/effects in other psychosocial health conditions.1,3
As recommended by a recent guideline of the National Institute for Health and 
Clinical Excellence in the UK,2 core interventions for early stage (eg, ,5 years) or 
acute schizophrenia should include psychoeducation, medication management, and 
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family support. They should also include those aiming 
to improve their insight into and self-management of the 
illness. However, most current approaches to psychosocial 
intervention have less attention in patients’ acceptance of 
schizophrenia and incomprehensible and stressful experi-
ences of the psychotic symptoms.4,5 Many of them may also 
contain limited strategies in empowering self-management 
of the illness.1,4 It has also increasingly been recognized 
that patients would be unable, inconvenient, or disempow-
ered to participate in lengthy (at least 6–9 months) and 
knowledge/conceptual heavy-loaded psychoeducation, or 
other psychosocial intervention programs.6,7 With a dif-
ferential understanding of schizophrenia and insight into its 
treatment needed, these patients can better cope with their 
psychotic symptoms and related behaviors and subsequently 
improve their treatment adherence and other longer-term 
patient outcomes.8
Recent controlled trials suggested that the standardized 
mindfulness-based stress reduction (MBSR) or mindfulness-
based cognitive intervention programs are evidenced to 
empower patients’ self-care and symptom management, 
insight into the illness, and accepting and overcoming with 
distressing thoughts in depressive and anxious conditions.9,10 
Both approaches are found to be effective treatments of a wide 
variety of chronic physical and mental health problems.6,10,11 
A controlled trial by Chadwick et al5 in the UK tested the 
effectiveness of 5-session mindfulness groups followed by 
home practices for 11 schizophrenia sufferers with distress-
ing voices and paranoia on subjective well-being (mindful-
ness), symptom severity, and life functioning immediately 
after intervention. There is an increasing interest to find out 
whether mindfulness-based intervention can be important 
for people with schizophrenia who are often characterized 
by unexpectedly low adherence to treatments, or only par-
tially responsive to standard treatment and/or psychosocial 
interventions. These characteristics lead to a chronic course 
of illness and frequent relapses.3
Findings of two controlled trials also suggest that Accep-
tance and Commitment Therapy with a strong mindfulness 
component can significantly reduce psychotic patients’ 
rehospitalization.9,12 These findings provide better under-
standing of mediating the patients’ distress in response to 
psychotic symptoms. This is opined to be a premise that 
patients are distressed not by the symptoms but by the mean-
ing they constructed for these symptoms and subsequent 
emotional responses.9,13
Williams et al14 suggested that the positive effects of 
mindfulness programs could be mediated/attributed by 
reductions of overgeneral memory and ruminative thinking 
and improvements in meta-awareness and specificity of 
describing psychiatric symptoms, which in turn might lead to 
much decrease in negative thoughts and depressive or anxiety 
reactions. A few recent case/cohort and quasi-experimental 
(nonrandomized) studies of mindfulness-based intervention 
in schizophrenia reported short- to medium-term patient 
outcomes (eg, ,6 months),6,15,16 suggesting its potential 
effectiveness to reduce distressing thoughts or images and 
disorganization of thoughts.
Nevertheless, most mindfulness interventions have been 
developed and tested in Western populations; it is uncer-
tain whether this approach to psychosocial intervention 
can be applicable to Asian/Chinese populations who have 
an external locus of control and less self-affirmation and 
openness to experience attitudes.17,18 With these knowledge 
gaps in mind, a mindfulness-based psychoeducation inter-
vention was designed and tested in Hong Kong Chinese 
people with schizophrenia spectrum disorders to evaluate 
its effects on a wide variety of patient outcomes such as 
psychotic symptoms, rehospitalizations, functioning, and 
insight into the illness.
aims and hypotheses
This randomized controlled trial tested the effects of a 
mindfulness-based psychoeducation group program (MPGP) 
(in addition to usual psychiatric care) for Chinese patients 
with schizophrenia spectrum disorders, in comparison to one 
conventional psychoeducation group program (CPGP) or 
treatment-as-usual (TAU) only, over a 6-month follow-up. 
Primary outcomes were the participants’ functioning and 
rehospitalization rate, whereas secondary outcomes included 
these patients’ psychotic symptoms, insight into illness, 
and progress of recovery. We hypothesized that when com-
pared with those in the CPGP and TAU alone, the MPGP 
participants could indicate significantly greater improve-
ments over the 6-month follow-up in the following:
1. their functioning and rehospitalization rates (primary 
outcomes);
2. their insight into illness/treatment, symptom severity, and 
progress of recovery.
Methods
The multicenter, controlled trial adopted an assessor-blind, 
repeated-measures and three-arm design (subject recruitment 
between June and November 2014 and 6-month follow-up 
between December 2014 and October 2015). An intention-
to-treat (ITT) principle was used for data analysis and all 
participants were assessed with the same set of outcome 
measures over the follow-up period, regardless of the levels 
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of completion of or adherence to their intervention assigned.19 
This controlled trial was registered at ClinicalTrials.gov (Ref: 
NCT01667601; https://register.clinicaltrials.gov). Flow dia-
gram of the trial procedure is presented in Figure 1, according 
to the latest CONSORT statement.20
Participants and settings
The controlled trial was conducted at two psychiatric 
outpatient clinics in Hong Kong. About 1,200 patients 
with schizophrenia spectrum disorders (eg, schizophrenia 
and schizophreniform disorders) were attending the two 
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Figure 1 Flow diagram of the procedure of the controlled trial.
Abbreviations: cPgP, conventional psychoeducation group program; iTaQ, insight and Treatment attitudes Questionnaire; MPgP, mindfulness-based psychoeducation 
group program; PANSS, Positive and Negative Syndrome Scale; QPR, Questionnaire for the Process of Recovery; SLOF, Specific Level of Functioning Scale; 
TaU, treatment-as-usual.
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3100
Wang et al
outpatient clinics in each of the two clinics under study 
(N=2,400) at recruitment. Of 300 (25%) screened for 
eligibility in each clinic, 180 (60%) and 160 (55%) were 
found eligible and agreed to participate. As the sample size 
was planned to be 138 subjects, 69 (38% and 43%) were then 
randomly selected from each of the two clinics. At the clinics, 
all eligible patients were listed in terms of alphabetical 
order of their surnames; 69 of them were randomly selected 
from each patient list according to the computer-generated 
random numbers provided by an independent statistician, in 
which 14–15 (18%) of patients approached in each clinic 
refused to participate in this trial because of lack of inter-
est and time to participate. With informed written consent 
obtained, the 144 patients were invited and 138 agreed to 
participate (ie, response rate =95.8%).
Participants’ inclusion criteria included those Chinese 
outpatients who were 1) aged 18–60 and diagnosed with 
schizophrenia or its subtypes according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision;21 2) not .5 years of schizophrenia at recruitment; 
and 3) able to understand and communicate in Cantonese/
Mandarin/Chinese languages. Those outpatients were 
excluded if they got comorbidity of organic brain disorder 
and learning disability, were found mentally unstable or 
unfit for study participation by their psychiatrist, and/or had 
recently received (been receiving) psychoeducation or any 
structured psychosocial intervention(s).
After completed baseline measurement, the participants 
were randomly assigned into one of the three arms by using 
a set of computerized random numbers generated by the 
statistician with a stochastic minimization program (bal-
anced gender and symptom severity [Positive and Negative 
Syndrome Scale score {PANSS}] between groups).22
instruments
The primary outcomes of this study were patient functioning, 
Specific Level of Functioning Scale (SLOF),23 and average 
number and length of patients’ rehospitalizations in the past 
6 months.
The 43-item SLOF measured the patients’ levels of 
psychosocial functioning in schizophrenia,23 in terms of 
self-maintenance, social functioning, and community living 
skills. The scale was scored on a 5-point Likert scale (1, “fully 
dependent” to 5, “fully self-sufficient”). In schizophrenia, the 
Chinese version showed very good content validity, internal 
consistency with Cronbach’s alpha of 0.90–0.95, and test–
retest reliability (intraclass correlation =0.84–0.88).24,25
The PANSS assessed the symptom severity in psycho-
ses and its 30 items were rated on an 8-point Likert scale 
(0, “absent” to 7, “extreme”).22 The scale demonstrated 
satisfactory concurrent validity with other symptom scales 
(r=0.85–0.90), internal consistency with Cronbach’s alpha 
of 0.87–0.92, and test–retest reliability (intraclass correlation 
of 0.85–0.90) in Chinese psychotic patients.24
The secondary outcomes composed patients’ levels of 
recovery, Questionnaire about the Process of Recovery 
(QPR),26 and insight into illness/treatment, Insight and Treat-
ment Attitudes Questionnaire (ITAQ),27 psychotic symptoms, 
and PANSS.28
Patient’s level of recovery was measured with the QPR26 
with a panel of psychotic patients. The QPR was translated 
and validated by the research team,17 consisting of 22 items 
and three subscales (self-empowerment, effective interper-
sonal relationships, and rebuilding life). Its items were rated 
on a 5-point rating scale (0, “disagree strongly” to 4, “agree 
strongly”). The Chinese version demonstrated very satisfac-
tory internal consistency with Cronbach’s alphas of 0.88–0.90, 
sensitivity to contrasting (symptom severity) groups (t=4.68, 
P,0.01), and test–retest reliability at 2-week interval (intrac-
lass correlation =0.87–0.92) in psychotic patients.17,29
The ITAQ consisted of 22 items and assessed patients’ 
awareness and acceptance of mental illness and prescribed 
treatments,27 scoring on a 3-point Likert scale (0, “no insight” 
to 2, “good insight”). The Chinese ITAQ indicated very 
acceptable content validity, inter-rater reliability (intraclass 
correlation =0.82), and internal consistency with Cronbach’s 
alpha of 0.82.30
All outcome measures, including those Chinese versions 
(SLOF, QPR, and ITAQ), were validated and found reliable 
and valid in Chinese psychotic patients.17,24,25 In addition, 
at the three post-tests, Five Facet Mindfulness Question-
naire (FFMQ) was used to assess the participants’ levels 
of performance or practices made on five components of 
mindfulness skills (observing, describing, performing with 
awareness, not giving judgment of inner experiences, and 
not over-reacting to these experiences).6 Its items were 
rated on a 5-point scale (1, “very rarely true” to 5, “always 
true”). The FFMQ indicated satisfactory internal consistency 
(Cronbach’s α=0.76–0.92) and predictive power to psycho-
logical well-being and symptoms.31
Treatments
The MPGP consisted of 12 two-hour group sessions (12– 
15 patients per group) every 2 weeks (ie, totally 24 weeks). 
It was developed from the Kabat-Zinn’s MBSR program and 
modified for community mental health care service in Hong 
Kong.30 The content of a psychoeducation group interven-
tion validated in Hong Kong Chinese psychotic patients by 
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Chan et al32 and Chien and Bressington33 was also integrated 
into the MPGP. One trained psychiatric advanced practice 
nurse (with 5 years of psychiatric rehabilitation and 3 years of 
mindfulness group experiences) facilitated all the treatment 
groups in the two clinics. The mindfulness theory used in the 
MPGP targeted at enhancing patients’ awareness, acceptance, 
and management of their illness and psychotic symptoms; 
improving their insight into the illness/treatment; resolving 
the illness-related problems and their poor functioning, help-
seeking, and self-care.
The program contained seven domains, including 1) pro-
gram overview and engagement; 2) enhancing awareness and 
understanding of bodily sensations, thoughts, and feelings 
regarding illness experiences or symptoms; 3) guided body 
awareness and mindful exercises and homework practices; 
4) education workshop of illness (schizophrenia) manage-
ment; 5) encountering with and controlling negative thoughts 
and perceptions, and life difficulties caused by symptoms, 
and practicing most effective problem-solving strategies; 
6) behavioral rehearsals of means for relapse prevention; and 
7) effective mindfulness practices, utilization of community 
support resources, and making realistic future plans. The 
MPGP could also promote an individual’s restructure of indi-
vidual thoughts and emotions in specific traditional Chinese 
culture (beliefs and behaviors). For instance, during the early 
sessions, participants were encouraged to practice regularly 
(not less than twice daily and 20 minutes per practice) of 
focused attention of their bodily sensations, thoughts and 
feelings, and mindful exercises (on breathing and walking), 
in which the facilitator also focused on understanding their 
Chinese cultural beliefs/behaviors – strong interdependence, 
encouraging better mutual support, practicing expression 
of feelings openly, and exploring ways of looking at life 
situations among group members. Participants were also 
encouraged to cultivate an open/accepting attitude and posi-
tive thinking/responses to life problems and thus develop 
a “decentered” (passing events in mind) attitude on their 
thoughts/feelings.9,13 Details of the MPGP can be provided 
by the authors upon request.
The CPGP also consisted of 12 two-hour sessions (every 
2 weeks). The program adopted the group psychoeducation 
manual established by Chan et al32 and Lehman et al34 PORT 
program in the USA. Participants received education and 
psychological support by one advanced practice nurse (hav-
ing 6 years of experiences in psychiatric rehabilitation). The 
nurse was trained by the research team and one rehabilitation 
specialist (social worker) with a 2-day workshop, consisting 
of lectures (1 hour each), discussion, sharing experiences, and 
supervised practices for group sessions. The CPGP consisted 
of four phases: 1) program overview, engagement, and setting 
goals for illness management (two sessions); 2) mental health 
education and information sharing about schizophrenia and 
survival skills training (four sessions); 3) relapse prevention, 
resilience promotion, and life skills training (four sessions); 
and 4) reviews on learned knowledge and skills and estab-
lishing future plans (two sessions).
All of the group sessions were tape-recorded (with par-
ticipants’ consent) and reviewed for monitoring the progress 
and fidelity of the two programs between two sessions, by 
the research team, and then, they discussed and solved the 
problems encountered in the group sessions.
TAU comprised the routine psychiatric outpatient care 
received by all of the 138 participants, which was found 
similar between the two clinics. The services mainly included 
psychiatric consultation, treatments, and referrals for medical 
or specialized care by psychiatrist; brief education and 
information sharing about the illness and its treatments, and 
available health care services by nurses; advices/referrals 
on social welfare and finance by medical social worker; 
and individual/family counseling by clinical psychologist, 
whenever necessary.
Data collection procedure
The Human Research Ethics Committee of The Hong Kong 
Polytechnic University (HSEARS20140218003) and the 
two clinics granted the ethical approvals for this controlled 
trial. Voluntary participation was assured from each patient 
with informed written consent before recruitment made. 
All potential participants were asked for any clarifications 
needed, and their questions were responded with their satis-
faction. Confidentiality of the participants’ personal identity 
and data collected were assured and their right for refusal of 
or withdrawal from the study at all times without negative 
impact on their treatment plans.
After securing the patients’ consents, the research assis-
tant who was blind to the group allocation administered the 
baseline measurements (time 1) to the individual participants 
in the clinics and they were then randomly allocated into one 
of the three study arms by the first author. The participant 
lists were safely kept in a locked cabinet and concealed to the 
researchers, clinic staff, and outcome assessor (research assis-
tant) and the research assistant (blind to the group assignment) 
performed all of the outcome measurements and data entries, 
in order to avoid subjective bias.35 To minimize treatment 
contamination, the first author asked the participants not to 
discuss about their program received to clinic staff and copa-
tients.35 The last author concealed to sampling/intervention 
procedures checked the accuracy of all data entries.
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After that, all participants undertook the assigned 6-month 
intervention, and during the outpatient clinic follow-up, the 
research assistant conducted the outcome measurements 
(two post-tests): 1-week (time 2) and 6-month (time 3) 
postintervention. The frequency and length of psychiatric 
readmissions, and the total patients (per group) hospitalized 
in the past 6 months, were examined from the patient records 
system of the clinics. Types and dosages of psychotropic 
drugs were also recorded; and facilitating the comparison of 
the dosages of antipsychotics between groups and/or across 
studies, the dosages were converted into their haloperidol 
equivalents.36 While no psychoeducation or mindfulness 
intervention was found within TAU, the participants reported 
any structured psychological interventions received during 
the intervention and follow-up period.
The manuals of both the MPGP and CPGP were vali-
dated by an expert panel (two psychiatrists, four specialists 
in psychiatric rehabilitation from allied health professions 
such as mental health nurse, occupational therapist, and 
clinical psychologist, and two volunteer peer mentors or 
ex-patients). The panel assessed the clarity and appropri-
ateness on the topics, case examples, and practices of each 
manual independently. Most of the topics in these manuals 
were rated “very satisfactory” or “excellent” on both the 
clarity (90%–98%) and appropriateness (91%–96%). Only 
a few items were reworded on their ways/styles of expres-
sion, format, and/or terminology. Intervention fidelity was 
assessed with a checklist to assess adherence to the topics 
and instructions, as recommended by the National Institute of 
Health Behaviour Change Consortium.37 The research team 
rated on the group facilitator’s adherence to the manual items 
by viewing each tape-record against the checklist.
sample size calculation
Sample size estimation was made with reference to a few 
clinical trials of psychoeducation or mindfulness-based 
programs for people with psychotic disorders.8,10,17,24 The 
effect sizes of patient functioning and rehospitalization 
rates were between 0.48 and 0.86 in comparison to usual 
care only over a 6-month follow-up. In addition, one pilot 
three-arm controlled trial of mindfulness intervention for 
Chinese people with schizophrenia indicated that the effect 
sizes of level of functioning and length of readmissions at 
post-test (1 week following intervention) were 0.60 and 0.50, 
respectively.30 As the result, a total of 138 patients (n=46 per 
group) were required to detect any statistical differences on 
patient functioning and length/number of rehospitalizations 
between three study groups at moderate effect sizes of 0.50, 
power of 0.80 (two-sided, P,0.05), as well as a potential 
attrition rate of 20%.10,24,30
Data analysis
According to the principles of ITT, SPSS (IBM) for Win-
dows, version 22, was used to insert, check, and analyze the 
data of patients’ demographic and clinical characteristics 
and outcome variables. Homogeneity of study groups was 
examined by comparing the participants’ characteristics and 
baseline outcome scores between three groups and settings 
(two clinics or cities) using one-way analysis of variance 
(ANOVA) or chi-square tests (for dichotomous data). Any 
of these variables found significant different between groups 
would be treated as covariant(s) in the analyses of the treat-
ment effects. However, there were not any significant cor-
relation found on any of the characteristics and baseline data 
between groups or settings. Recognizing minimal violations 
of principles of multivariate model of analysis such as mul-
tivariate normality and equality of variance–covariance, the 
interaction (Group × Time) treatment effects were examined 
using the mixed-model multivariate or multivariate analy-
ses of variance (MANOVA) test.19 With significant results 
obtained in the MANOVA test, repeated-measures ANOVA 
test was then used to compare the patient outcomes (SLOF, 
rehospitalizations, QPR, ITAQ, and PANSS) and dosage 
of antipsychotic medication between groups across time 
(measurements). If these between-group comparisons were 
found significant, contrast tests (such as Helmert’s contrasts) 
were performed to examine any significant mean score dif-
ference (MD) (between-group) on individual outcomes (if 
found statistically significant in ANOVA test).19,38 Subgroup 
differences of the MPGP between two clinics, two cities, and 
those with low (,6 sessions) and high ($6 sessions) atten-
dance on the above outcomes showing significant results were 
also found, using ANOVA tests. Total number of patients 
rehospitalized over 6 months was compared between groups 
across measurements, using Kruskal–Wallis H test (if found 
significant, then analyzed by Mann–Whitney U test). The 
mean total scores of the FFMQ in the MPGP participants 
were compared between two post-tests. The level of statistical 
significance was set at 0.05.
Results
characteristics of study participants
There were 131 of the 138 participants (95%) who com-
pleted the interventions assigned (ie, failed to complete at 
least 5 sessions) and at least 1 post-test, and thus their data 
were included in final data analyses. Two in the MPGP 
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and CPGP alone and three in the TAU only were unable to 
contact at 1 week after the interventions (time 2), and two 
to four participants in the three study groups declined the 
follow-up (time 3) or withdrew from the study. Only those 
participants who could not complete both post-tests (times 2 
and 3) were not counted in the analysis of treatment effects 
(Figure 1). Reasons for withdrawal from participation and 
incompletion of the interventions were similar, including 
time inconvenience for attending the intervention (n=4), 
lack of interest to continue their study participation (n=4), 
and very poor mental condition (n=2). Intervention fidelities 
for the MPGP and CPGP were very promising, ranging from 
88.5% to 94.3% (average percentage of agreement =92.0%) 
and from 89.5% to 96.0% (average agreement =93.5%) in 
adherence to the intervention protocols, respectively.
The participants’ sociodemographic and clinical charac-
teristics (n=46 per study group) are summarized (Table 1). 
Their mean ages were 23.8–25.0 years (standard deviation 
[SD] =6.3–7.0), ranging from 18 to 39 years. Over 82% 
received oral antipsychotic medications with low/medium 
dosage (haloperidol equivalents ranged 3.0–8.5 mg/day).36 
About 50% were taking second-generation or blended mode 
(both first- and second-generation) of antipsychotic medica-
tions. There were no significant differences found on all of 
the characteristics between the three study groups (whereas 
P=0.18–0.38) as shown in Table 1, as well as between two 
clinics under study (P.0.14). In addition, there were no 
correlations between these characteristics and the baseline 
outcome scores (Spearman’s r
p
,0.11), indicating minimal 
covariate effect to the outcome variables.
Treatment effects
Mean (and SD) values of baseline outcome scores and 
two post-tests for the participants are presented in Table 2. 
There were no significant differences on the baseline mean 
scores of all study outcomes between the three groups 
(P=0.20–0.31). There were only eight sets of missing data 
(mainly on SLOF, QPR, and ITAQ) found on the outcomes 
of two to four participants in the three groups at time 2 or 3, 
and these created very minimal differences in the results of 
the outcome analyses when tested by different missing data 
management strategies. Hence, these missing data were filled 
up by bringing forward individual participants’ previous data 
in the final data analysis.38
There were no violations of the assumptions for mul-
tivariate analysis of outcome variables (eg, nonsignificant 
homogeneity of variance–covariance matrices with Box’s 
test at P=0.18 and equality of variances with Levene’s 
Equality of Error Variances test at P=0.20) between groups 
and low correlations between these outcomes (r=0.10–0.28). 
Mixed-model MANOVA test was performed, resulting in 
a significant interactive (Group × Time) treatment effect 
on the six outcomes (SLOF, number, and length of rehos-
pitalizations, PANSS, ITAQ, and QPR) between groups 
(F[6,130]=7.02, P=0.001, Wilks’ λ=0.85; partial η2=0.54), 
with a large effect size.38 When between-group effects 
for individual outcome variables were assessed indepen-
dently (F values in Table 2), the MPGP showed significant 
greater improvements on four study outcomes, including 
patients’ functioning (F[2,129]=6.98, P=0.0009) and its 
subscales (P=0.003–0.0007); psychotic symptom severity 
(F[2,129]=6.20, P=0.003) and both positive and negative 
symptom subscales (P=0.001 and 0.005, respectively), 
progress on recovery (F[2,129]=5.83, P=0.005), and insight 
into their illness/treatment (F[2,129]=5.10, P=0.01), than the 
CPGP and/or TAU alone.
The MDs of the above four outcomes in contrast tests indi-
cated significant differences between groups as follows:
•	 Level of functioning (SLOF) in the MPGP significantly 
better improved at times 2–3 (MD =16.8 and 30.6, P=0.008 
and 0.0009, respectively) in comparison to TAU alone, 
whereas the MPGP also indicated greater improvements in 
their functioning at the post-tests than the CPGP (P=0.02 
and 0.006). In addition, the CPGP indicated greater func-
tional improvements at times 3 and 4 (MD =7.9 and 11.4, 
P=0.05 and 0.01) than the TAU alone.
•	 Psychotic symptoms (PANSS score) in the MPGP signifi-
cantly reduced at time 2–3 (MD =8.5 and 18.5, P=0.01 
and 0.003, respectively), whereas the TAU alone indi-
cated consistent increase in symptom severity across time 
(from M =88.1±9.0 at baseline, M =90.2±10.1 at time 1 
to M =97.8±10.8 at time 2). The MPGP also indicated 
significant greater reduction of psychotic symptoms than 
the CPGP at time 3 (M =70.0±10.0 vs M =84.1±9.5).
•	 Progress of recovery from the illness (QPR score) in 
the MPGP participants significantly better improved at 
times 2 and 3 (MD =3.4 and 8.3, P=0.01 and 0.0008, 
respectively) than the TAU-alone group, whereas 
the CPGP participants indicated significantly better 
recovery condition than the TAU alone group at time 3 
(MD =2.5, P=0.04). In addition, the MPGP showed sig-
nificantly better recovery condition than the CPGP at 
time 3 (P=0.001).
•	 Insight into illness/treatment (ITAQ score) of the MPGP 
significantly greater improved at time 3 (MD =5.4, 
P=0.001) than both the CPGP and TAU alone, whereas 
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Table 1 characteristics of MPgP, cPgP, and TaU participants (N=138)
Characteristics MPGP (n=46), f (%) 
or M ±	SD
CPGP (n=46), f (%) 
or M ±	SD
TAU (n=46), f (%) 
or M ±	SD
Chi-square or 
ANOVA testa
P-value
Gender χ2=1.04 0.38
Male 24 (52.1) 23 (50.0) 25 (54.3)
Female 22 (47.8) 23 (50.0) 21 (45.7)
Age (years) 23.8±6.8,  
ci=16.9–30.3 
24.1±6.3,  
ci=17.6–30.6
25.0±7.0,  
ci=17.8–31.9
F=1.13 0.30
18–25 18 (39.1) 15 (32.6) 18 (39.1)
26–30 15 (32.6) 18 (29.1) 16 (34.8)
31–35 10 (21.7) 9 (19.6) 9 (19.6)
.35 3 (6.5) 4 (8.7) 3 (6.5)
Education level χ2=1.31 0.33
Primary school or below 8 (17.4) 7 (15.2) 7 (15.2)
secondary school 30 (65.2) 30 (65.2) 29 (63.0)
University or above 8 (17.4) 9 (19.6) 10 (21.8)
Primary diagnosis χ2=1.25 0.28
schizophrenia 20 (43.5) 19 (41.3) 19 (41.3)
schizophreniform disorder 12 (26.1) 13 (28.3) 12 (26.1)
schizoaffective disorder 10 (21.7) 10 (21.7) 9 (19.6)
Other psychotic disorders 4 (8.7) 4 (8.7) 6 (13.0)
Monthly household income (HKD)b 15,081±4,013, 
ci=11,523–19,205
16,712±4,702, 
ci=11,601–20,520
17,005±3,981, 
ci=13,257–20,995
F=1.40 0.25
10,000 or below 7 (15.2) 7 (15.2) 6 (13.0)
10,001–20,000 17 (37.0) 16 (34.8) 16 (34.8)
20,001–30,000 18 (39.1) 20 (43.5) 20 (43.5)
.30,000 4 (8.7) 3 (6.5) 4 (8.7)
Duration of illness (years) 2.0±1.0, range: 0.2–3.0, 
ci=0.9–3.0
2.1±0.9, range: 0.4–3.0, 
ci=1.2–3.1
2.0±0.9, range: 0.5–2.9, 
ci=1.1–3.0
F=1.45 0.24
,1 14 (30.4) 13 (28.3) 13 (28.3)
1–2 14 (30.4) 15 (32.6) 15 (32.6)
2–3 10 (21.8) 10 (21.8) 11 (23.9)
3–5 8 (17.4) 8 (17.4) 7 (15.2)
Number of family members living with 
patient
χ2=1.65 0.23
None 10 (21.7) 9 (19.6) 9 (19.6)
1–2 29 (63.1) 28 (60.9) 30 (65.2)
3–4 7 (15.2) 9 (19.6) 7 (15.2) 
Type of medication χ2=1.23 0.28
conventional antipsychotics (eg, haloperidol) 16 (34.8) 15 (32.6) 17 (37.0)
atypical antipsychotics (eg, risperidone) 18 (39.1) 18 (39.1) 17 (37.0)
Antidepressants (eg, fluoxetine) 7 (15.2) 6 (13.1) 7 (15.2)
Blended modec 5 (10.9) 7 (15.2) 5 (10.9)
Use of psychiatric services χ2=1.82 0.20
Medical consultation and treatment planning 43 (93.5) 46 (100.0) 44 (95.7)
Nursing advice on services and brief education 40 (87.0) 39 (84.8) 40 (87.0)
Social welfare and financial advices 38 (82.6) 37 (80.4) 36 (78.3)
individual/family counseling 20 (43.5) 18 (39.1) 15 (32.6)
Dosage of medicationd χ2=1.98 0.18
high 10 (21.7) 10 (21.7) 11 (23.9)
Medium 20 (43.5) 19 (41.3) 20 (43.5)
low 16 (34.8) 17 (37.0) 15 (32.6)
Notes: aaNOVa test (F-test, df=136) was used to compare the participants’ sociodemographic variables in interval or continuous level of measurement between three study 
groups; otherwise, chi-square tests were used. bUs$1=hKD 7.80. cPatients were taking more than one type of psychotropic medication such as the use of either conventional 
and atypical antipsychotic or atypical antipsychotic together with one antidepressant. dDosage levels of psychotropic/antipsychotic medications were compared with the 
average dosage of medication taken by the patients in haloperidol-equivalent mean values.36
Abbreviations: ANOVA, analysis of variance; CI, 95% confidence interval; CPGP, conventional psychoeducation group program; f, frequency; M, mean; MPGP, mindfulness-
based psychoeducation group program; sD, standard deviation; TaU, treatment-as-usual or usual psychiatric outpatient care.
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the CPGP and TAU alone group indicated very mild 
changes in their insight scores.
Furthermore, the MPGP had significantly less patients 
being rehospitalized into psychiatric units over the past 
6 months than both the CPGP and TAU alone at time 3 
(Kruskal–Wallis test value =8.41, P=0.005, 5 [11%] vs 12 
[27%] for CPGP vs 16 [37%] for TAU alone). The signifi-
cant outcomes mentioned above (SLOF, PANSS, QPR, and 
ITAQ) did not show any significant differences between 
the two clinics (P=0.15–0.26) and between the MPGP 
with low (,6 sessions) and high ($6 sessions) attendance 
(P=0.10–0.20), using repeated-measures ANOVA tests. As 
shown in Table 2, the mindfulness performance (FFMQ 
score) in the MPGP significantly improved from time 1 to 
time 2 (paired t=7.12, P=0.003). However, there were no sig-
nificant differences on the dosages and types of antipsychotic 
medications and psychosocial interventions used (eg, fam-
ily/individual psychotherapy and medication management) 
between groups over follow-up (P.0.25).
Discussion
This randomized controlled trial was one of the few con-
ducted to test the effects of a MPGP for people with schizo-
phrenia spectrum disorders and its comparative effectiveness 
with a common and well-accepted psychoeducation group 
program. The MPGP for these Chinese patients demonstrated 
more superior and wider variety of positive results than 
the CPGP, as well as the usual psychiatric care alone. It is 
highly encouraging and important to find out that the MPGP 
can produce significantly greater improvements in different 
aspects of patient functioning (including self-maintenance, 
social interactions, and living skills), both positive and 
negative (psychotic) symptoms, and insight into their illness 
and treatments over the 6-month follow-up, with moderate 
large effect sizes. The MPGP can also enhance these patients’ 
progress of recovery (eg, accepting responsibilities and tasks 
to rebuild one’s life and ability to engage in self-reflection on 
the ways that recovery is influenced by one’s interpersonal 
relationships).26
Despite that the MPGP could not demonstrate its effect 
on reducing readmissions significantly, the average number 
and duration of rehospitalizations among the MPGP par-
ticipants progressively decreased over the follow-up period, 
whereas the other two study groups had slightly changes or 
increases in these rehospitalization rates across time. In con-
sonance with these positive results, the MPGP participants 
could continuously and significantly improve their mind-
fulness performance (FFMQ scores) from postintervention 
to the 6-month follow-up. These findings may fill in the 
knowledge gap suggested by recent systematic reviews that 
the CPGPs might show significant short- to medium-term 
effects in mainly symptom control or improving mental state 
and relapse prevention in schizophrenia and its spectrum 
disorders.2,8,39
It is important to note that the MPGP in this study can 
also exert moderately large effects on negative symptoms, 
which has rarely been found in most of the current psychiatric 
treatments or psychosocial interventions in schizophrenia.40 
As recommended by Coelho et al,11 the therapeutic com-
ponents of mindfulness (or meditation), including self-
awareness, self-empowering, acceptance, and compassion, 
are integrated into the mindfulness-based intervention to 
enhance one’s motivation to self-regulate or manage their 
illness, symptoms, and related behaviors, thus being likely to 
mediate the other patient outcomes. However, the therapeutic 
mechanisms of mindfulness training to improve the control 
of psychotic symptoms in schizophrenia are still unknown, 
thus needing to be explored in future research.
Importantly, the findings can support the benefits of the 
MPGP in improving patients’ psychosocial functioning and 
inducing their insight into the illness (schizophrenia). In line 
with the goal of psychiatric treatment and rehabilitation, it is 
very crucial for psychotic patients to be integrated success-
fully into their community and living independently there.5,41 
In addition, psychotic patients can have better adherence to 
their treatment regimen and more able to perform self-care 
and management of the illness if their insight into the illness 
has been enhanced.42 Indeed, most of the current psycho-
education or psychosocial interventions have not yet been 
insight-oriented and thus unable to have significant impact 
on inducing patients’ insight into their illness similar to this 
MPGP. These findings provide support for combined effects 
of mindfulness training and psychoeducation in facilitat-
ing patients with schizophrenia to be recovered (ie, having 
symptom alleviation and improvement of functioning, thus 
achieving fullest capacity and independence of living) at the 
earliest possible in the community-based rehabilitation.10
Previous controlled trials that indicated significant 
effects5,43,44 were mainly designed with quasi-experimental 
and feasibility or pilot testing, using small-sized samples with 
more chronic or longer duration of illness and/or comorbidi-
ties of other mental illnesses. Those trials were conducted 
in a single study site and adopted combined approaches to 
cognitive therapy (eg, meta-cognitive therapy, attention 
training technique, cognitive-behavioral or acceptance 
and commitment therapy); they reported higher attritions 
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(25%–50%) and noncompletion rates (30%–50%) and used 
a few narrowly focused patient outcomes (mainly symptom 
severity and level of mindfulness). This study can provide 
higher quality of evidence about the effects of mindfulness-
based intervention by using randomized controlled trial 
design with adequate randomized sample (study power) in 
early stage of schizophrenia spectrum disorders, low attri-
tion and noncompletion rates, and a wider variety of patient 
outcomes, when compared with a CPGP. Nevertheless, fur-
ther multisite, randomized, controlled trials in more diverse 
patient populations with different comorbidities and a longer-
term follow-up, with different structures (eg, individual 
versus group basis) of the intervention, and/or adopting other 
clinical outcomes (eg, service utilization and quality of life) 
are recommended.
In contrast to the common beliefs or cautions about the 
possible impacts of mindfulness training on exacerbation of 
psychotic symptoms during meditation practices or mindful 
exercises,5,13,40 this clinical trial provides supporting evidence 
for the MPGP that can largely improve psychotic patients’ 
mental and psychosocial health conditions and gain insight 
into the illness, thus reducing risk of their relapse. In this 
study, there was not any adverse event or reaction relating 
to the mindfulness-based intervention noted. A few core 
elements of mindfulness training and psychoeducation 
might constitute the therapeutic components of the MPGP, 
including “being aware and accepting/controlling thoughts, 
feelings and emotions”, “coping and problem-solving abil-
ity”, “self-empowerment and regulation”, and “seeking help 
and support”,4,8,10 which have not been examined or tested 
in this study. Therefore, further research is recommended to 
examine these potential therapeutic components individually 
or interactively and mechanism of actions of this psychoso-
cial intervention (MPGP) used in this study.
The benefits of the MPGP to these psychotic patients can 
be started from responding to their symptoms in an inten-
tional and acceptable manner through an improvement of 
their awareness, acceptance, and relationships with unwanted 
thoughts and emotions/feelings. Throughout the mindfulness 
practices, the intervention may help an individual develop 
cognitive changes (eg, higher acceptance and motivation 
in rehabilitation and management of the illness), gradually 
become more focused on the present, and finally relieved 
from the symptom-related distress.45 Recently, there have also 
been suggestions that mindfulness-based interventions may 
function through top-down and/or bottom-up mechanisms 
of cognitive remediation.46 Top-down mechanism occurs in 
the development of interoceptive attention to visceral bodily 
sensations, facilitating through daily mindful practices such 
as breathing monitoring. As the meditation practice deepens, 
interoceptive attention networks increase and alter informa-
tion processing in the brain to enhance perceptual experience 
and, at the same time, promote reduced conceptual cortical 
activity.47 Bottom-up regulations have also been suggested 
as modulation of emotion-generative brain regions (limbic) 
without involving the frontal regions for cognitive regulation 
(eg, appraisal and suppression).46,48 Therefore, it is important 
to further examine in future research whether the patients 
who have undertaken the MPGP can experience such cog-
nitive changes and reduce the distress relating to psychotic 
symptoms; hence, the results may inform the physiological 
benefits or a new cognitive remediation model for psychotic 
symptoms (eg, hallucinations and delusions), as suggested 
by Freeman et al.49
In addition, the MPGP participants in this study could 
demonstrate significantly higher improvements in most of 
the primary and secondary outcomes than the CPGP and 
TAU alone, over 6-month postintervention. Langer et al’s43 
feasibility study of a mindfulness-based cognitive therapy 
for people with early psychosis also reported significant 
effects on their ability to respond mindfully to stressful 
internal events (eg, distressing thoughts and images) at the 
end of the intervention. However, the patients’ symptom 
severity and unwillingness to come into or stay in contact 
with internal experience were not significantly improved. 
Its limitations on adherence to mindfulness training and 
practices, small sample size, and taking adequate care of 
patients’ educational and resources needs were addressed 
in this study. Indeed, the MPGP can demonstrate more 
substantial and diverse therapeutic effects to those patients 
with early stage of schizophrenia (ie, within 5 years of the 
illness), in consistent with the findings of Moritz et al’s44 
mindfulness intervention trial.
achieving better participation and 
completion rates
While the anticipated benefits were induced by the mind-
fulness-based practices with the 12 biweekly face-to-face 
training/education, those review and learning for self-practice 
sessions may motivate the participants to continue attending 
and complete the program. However, there can also be a 
few reasons to possibly explain about such low dropout and 
noncompletion rates. First, the patients in the early stage of 
the illness who agreed to participate in the interventions (and 
study) could be highly motivated to improve their illness con-
dition and much involved in their community rehabilitation or 
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any interventions potentially beneficial to the illness. Second, 
the conditions such as patients being young, highly educated, 
and having family support and a satisfactory financial situ-
ation, together with a culture of respect and trust for profes-
sionals such as clinical managers and therapists,33 prevailed 
among Chinese/Asian populations. Last, there might be very 
few structured psychosocial or mindfulness-based education 
programs/services available for, or accessible to, Chinese 
patients with early schizophrenia or psychosis.2,17,33
limitations and implications
Although this randomized controlled trial has strong internal 
validity using a random sample from two outpatient clinics 
in Hong Kong and very satisfactory treatment fidelity, a few 
main limitations should be noted. First, the participants who 
had mainly a short duration of illness and were volunteers 
to participate were very likely to adhere to and complete 
the intervention and be motivated to get improved in their 
health outcomes. In addition, all of them were not blind to the 
intervention allocation, which could produce an expectation 
or desirable response bias.
Second, the sample consisted of patients with a higher 
education level, low- to moderate levels of antipsychotic 
medication, and a better family support. Despite having 
randomized samples from two clinics, the characteristics 
of the participants were selective and thus might not be 
representative of the wider patient (schizophrenia) popula-
tions in Hong Kong. To increase the generalization of the 
findings to these patient populations, the sample could have 
included those with different chronicity and severity of 
schizophrenia, as well as those with different comorbidities 
of other mental disorders.2 As mentioned in the above discus-
sion, this selective sample might also contribute to higher 
levels of completion and lower dropout rates. Therefore, the 
findings of this study may not be fully generalizable to the 
Hong Kong/Chinese populations of schizophrenia spectrum 
disorders, and further research in this patient group with dif-
ferent sociodemographic, illness, and ethnic characteristics 
is, therefore, recommended.
Third, although the levels of performance in mindfulness 
practice (FFMQ score) in the MPGP participants have been 
monitored (ie, significantly enhanced from the postinterven-
tion to 6-month follow-up), their adherence and regularity of 
daily practices could be difficult to standardize/address as what 
may be achieved by applying a manual- or protocol-driven 
psychoeducation program.13 The extent of engagement and 
review on mindfulness practices with the therapists might 
contribute to much psychological and/or treatment effects in 
these patients;29 but these impacts have not been examined. 
In addition, the individual/combined benefits of multiple 
components of mindfulness and psychoeducation approaches 
in the MPGP are not known in this trial. To better understand 
the therapeutic effects of mindfulness-based intervention and 
its components, the relationships between patient outcomes 
and action mechanisms of the MPGP, as well as the potential 
moderators (eg, symptom severity and duration of and insight 
into illness) and mediators (eg, acceptance, psychological 
flexibility, and compassion) of outcomes,11 should also be 
investigated in future controlled trials.
Third, this controlled trial was planned by the research 
team and conducted by the extensively trained advanced 
practice psychiatric nurses, thus increasing risk of allegiance 
bias,50 although the study outcomes were measured by an 
independent assessor. This might also reduce the applicability 
of the intervention to the usual psychiatric outpatient care 
that is likely to favor brief and user-friendly or even mobile/
online modes of interventions with simple training. Together 
with no concealment of intervention participation to clinic 
staff, the participants could have shared and discussed the 
study participation/intervention received with the staff and 
thus might inflate/overstate the treatment effects.20
Last, there were changes in the symptom severity but not 
the remission rates among the participants over 6 months of 
follow-up. The MPGP participants demonstrating statistically 
much reduced symptoms over the follow-up than the other 
study groups might not represent the full symptom remis-
sions (ie, 4-month ratings of all PANSS items as score #3).51 
Full remissions among the patients can better reveal their 
clinically significant and meaningful changes in psychiatric 
symptoms and thus illness condition or recovery.
Conclusion
Notwithstanding its limitations, the randomized controlled 
trial provides important evidence to support the medium-term 
(6 months) effect of a MPGP for patients with schizophrenia 
spectrum disorders. Compared with CPGP and usual outpa-
tient care alone, the MPGP participants reported significant 
positive changes in a few psychosocial outcomes, including 
improved different aspects of functioning, reduced psychotic 
symptoms, and enhanced progress of recovery and insight 
into their illness across the follow-up. This controlled trial 
supports the use of the MPGP to aid for relapse prevention 
and improving psychosocial health and functioning, and 
thus the community-based rehabilitation for patients with 
early schizophrenia and related disorders. The findings sup-
port further research on the mindfulness-based program in 
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psychotic disorders with those from wider sociodemographic 
and clinical characteristics in Asian/Chinese populations, 
or those with chronic or comorbid mental illness and/or 
study settings.
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